<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38110940</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1423-0127</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Dec</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of biomedical science</Title><ISOAbbreviation>J Biomed Sci</ISOAbbreviation></Journal><ArticleTitle>A novel mucosal bivalent vaccine of EV-A71/EV-D68 adjuvanted with polysaccharides from Ganoderma lucidum protects mice against EV-A71 and EV-D68 lethal challenge.</ArticleTitle><Pagination><StartPage>96</StartPage><MedlinePgn>96</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">96</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12929-023-00987-3</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Human enteroviruses A71 (EV-A71) and D68 (EV-D68) are the suspected causative agents of hand-foot-and-mouth disease, aseptic meningitis, encephalitis, acute flaccid myelitis, and acute flaccid paralysis in children. Until now, no cure nor mucosal vaccine existed for EV-A71 and EV-D68. Novel mucosal bivalent vaccines are highly important for preventing EV-A71 and EV-D68 infections.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, formalin-inactivated EV-A71 and EV-D68 were used as antigens, while PS-G, a polysaccharide from Ganoderma lucidum, was used as an adjuvant. Natural polysaccharides have the characteristics of intrinsic immunomodulation, biocompatibility, low toxicity, and safety. Mice were immunized intranasally with PBS, EV-A71, EV-D68, or EV-A71 + EV-D68, with or without PS-G as an adjuvant.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The EV-A71 + EV-D68 bivalent vaccine generated considerable EV-A71- and EV-D68-specific IgG and IgA titres in the sera, nasal washes, saliva, bronchoalveolar lavage fluid, and feces. These antibodies neutralized EV-D68 and EV-A71 infectivity. They also cross-neutralized infections by different EV-D68 and EV-A71 sub-genotypes. Furthermore, compared with the PBS group, EV-A71 + EV-D68 + PS-G-vaccinated mice exhibited an increased number of EV-D68- and EV-A71-specific IgA- and IgG-producing cells. In addition, T-cell proliferative responses, and IFN-γ and IL-17 secretion in the spleen were substantially induced when PS-G was used as an adjuvant with EV-A71 + EV-D68. Finally, in vivo challenge experiments demonstrated that the immune sera induced by EV-A71 + EV-D68 + PS-G conferred protection in neonate mice against lethal EV-A71 and EV-D68 challenges as indicated by the increased survival rate and decreased clinical score and viral RNA tissue expression. Taken together, all EV-A71/EV-D68 + PS-G-immunized mice developed potent specific humoral, mucosal, and cellular immune responses to EV-D68 and EV-A71 and were protected against them.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings demonstrated that PS-G can be used as a potential adjuvant for EV-A71 and EV-D68 bivalent mucosal vaccines. Our results provide useful information for the further preclinical and clinical development of a mucosal bivalent enterovirus vaccine against both EV-A71 and EV-D68 infections.</AbstractText><CopyrightInformation>© 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yu-Li</ForeName><Initials>YL</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Pei-Yun</ForeName><Initials>PY</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chin</LastName><ForeName>Chiao-Li</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Kuan-Ting</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Jing-Yi</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Chun-Kei</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Cheng-Sheng</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Siao-Cian</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiang</LastName><ForeName>Bor-Luen</ForeName><Initials>BL</Initials><Identifier Source="ORCID">0000-0002-6705-0286</Identifier><AffiliationInfo><Affiliation>Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan. gicmbor@ntu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan. gicmbor@ntu.edu.tw.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. gicmbor@ntu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>108-2321-B-002-006</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country /></Grant><Grant><GrantID>109-2320-B-002-013</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country /></Grant><Grant><GrantID>110-2320-B-002-036</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country /></Grant><Grant><GrantID>111-2320-B-002-035-MY3</GrantID><Agency>Ministry of Science and Technology, Taiwan</Agency><Country /></Grant><Grant><GrantID>110-O09</GrantID><Agency>National Taiwan University Hospital</Agency><Country /></Grant><Grant><GrantID>111-S0053</GrantID><Agency>National Taiwan University Hospital</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Sci</MedlineTA><NlmUniqueID>9421567</NlmUniqueID><ISSNLinking>1021-7770</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000629404">acute flaccid myelitis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="Y">Enterovirus D, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020940" MajorTopicYN="Y">Reishi</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute flaccid myelitis</Keyword><Keyword MajorTopicYN="N">Acute flaccid paralysis</Keyword><Keyword MajorTopicYN="N">Adjuvant</Keyword><Keyword MajorTopicYN="N">Enterovirus A71</Keyword><Keyword MajorTopicYN="N">Enterovirus D68</Keyword><Keyword MajorTopicYN="N">Ganoderma lucidum polysaccharide</Keyword><Keyword MajorTopicYN="N">Intranasal</Keyword><Keyword MajorTopicYN="N">Mucosal vaccine</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>20</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>19</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38110940</ArticleId><ArticleId IdType="pmc">PMC10729491</ArticleId><ArticleId IdType="doi">10.1186/s12929-023-00987-3</ArticleId><ArticleId IdType="pii">10.1186/s12929-023-00987-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oberste MS, Maher K, Schnurr D, Flemister MR, Lovchik JC, Peters H, et al. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J Gen Virol. 2004;85:2577–2584. doi: 10.1099/vir.0.79925-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.79925-0</ArticleId><ArticleId IdType="pubmed">15302951</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sheng J, Fokine A, Meng G, Shin W-H, Long F, et al. Structure and inhibition of EV-D68, a virus that causes respiratory illness in children. Science. 2015;347:71–74. doi: 10.1126/science.1261962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1261962</ArticleId><ArticleId IdType="pmc">PMC4307789</ArticleId><ArticleId IdType="pubmed">25554786</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J, Shen L, Wu J, Zou X, Gu J, Chen J, et al. Enterovirus A71 proteins: structure and function. Front Microbiol. 2018;9:286. doi: 10.3389/fmicb.2018.00286.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2018.00286</ArticleId><ArticleId IdType="pmc">PMC5826392</ArticleId><ArticleId IdType="pubmed">29515559</ArticleId></ArticleIdList></Reference><Reference><Citation>Oermann CM, Schuster JE, Conners GP, Newland JG, Selvarangan R, Jackson MA. Enterovirus D68. A focused review and clinical highlights from the 2014 U.S. Outbreak. Ann Am Thorac Soc. 2015;12:775–781. doi: 10.1513/AnnalsATS.201412-592FR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/AnnalsATS.201412-592FR</ArticleId><ArticleId IdType="pubmed">25714788</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304–309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip CCY, Lau SKP, Woo PCY, Yuen KY. Human enterovirus 71 epidemics: what’s next? Emerg Health Threats J. 2013;6:19780. doi: 10.3402/ehtj.v6i0.19780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/ehtj.v6i0.19780</ArticleId><ArticleId IdType="pmc">PMC3772321</ArticleId><ArticleId IdType="pubmed">24119538</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY. Enterovirus 71 in Taiwan. Pediatr Neonatol. 2008;49:103–112. doi: 10.1016/S1875-9572(08)60023-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1875-9572(08)60023-6</ArticleId><ArticleId IdType="pubmed">19054914</ArticleId></ArticleIdList></Reference><Reference><Citation>Puenpa J, Wanlapakorn N, Vongpunsawad S, Poovorawan Y. The history of Enterovirus A71 outbreaks and molecular epidemiology in the Asia-Pacific region. J Biomed Sci. 2019;26:75. doi: 10.1186/s12929-019-0573-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0573-2</ArticleId><ArticleId IdType="pmc">PMC6798416</ArticleId><ArticleId IdType="pubmed">31627753</ArticleId></ArticleIdList></Reference><Reference><Citation>Schieble JH, Fox VL, Lennette EH. A probable new human picornavirus associated with respiratory diseases. Am J Epidemiol. 1967;85:297–310. doi: 10.1093/oxfordjournals.aje.a120693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.aje.a120693</ArticleId><ArticleId IdType="pubmed">4960233</ArticleId></ArticleIdList></Reference><Reference><Citation>Sejvar JJ, Lopez AS, Cortese MM, Leshem E, Pastula DM, Miller LA, et al. Acute flaccid myelitis in the United States, August–December 2014: Results of Nationwide Surveillance. Clin Infect Dis. 2016;63:737–745. doi: 10.1093/cid/ciw372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciw372</ArticleId><ArticleId IdType="pmc">PMC5709818</ArticleId><ArticleId IdType="pubmed">27318332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugo D, Krogstad P. Enteroviruses in the early 21st century: new manifestations and challenges. Curr Opin Pediatr. 2016;28:107–113. doi: 10.1097/MOP.0000000000000303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0000000000000303</ArticleId><ArticleId IdType="pmc">PMC4750492</ArticleId><ArticleId IdType="pubmed">26709690</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura T, Oshitani H. Global reemergence of enterovirus D68 as an important pathogen for acute respiratory infections. Rev Med Virol. 2014;25:102–114. doi: 10.1002/rmv.1820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1820</ArticleId><ArticleId IdType="pmc">PMC4407910</ArticleId><ArticleId IdType="pubmed">25471236</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster CB, Friedman N, Carl J, Piedimonte G. Enterovirus D68: a clinically important respiratory enterovirus. Cleve Clin J Med. 2015;82:26–31. doi: 10.3949/ccjm.82a.14166.</Citation><ArticleIdList><ArticleId IdType="doi">10.3949/ccjm.82a.14166</ArticleId><ArticleId IdType="pubmed">25552624</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy A, Roberts JA, Lang J, Tempone S, Kesson A, Dofai A, et al. Enterovirus D68 disease and molecular epidemiology in Australia. J Clin Virol. 2015;69:117–121. doi: 10.1016/j.jcv.2015.06.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2015.06.079</ArticleId><ArticleId IdType="pubmed">26209392</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang YP, Lin TL, Lin TH, Wu HS. Molecular and epidemiological study of enterovirus D68 in Taiwan. J Microbiol Immunol Infect. 2017;50:411–417. doi: 10.1016/j.jmii.2015.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2015.07.015</ArticleId><ArticleId IdType="pubmed">26458357</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Bian L, Xu M, Liang Z. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD) Expert Rev Vaccines. 2016;15:599–606. doi: 10.1586/14760584.2016.1138862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/14760584.2016.1138862</ArticleId><ArticleId IdType="pubmed">26732723</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen-Tran H, Messacar K. Preventing enterovirus A71 disease: another promising vaccine for children. Lancet. 2022;399:1671–1673. doi: 10.1016/S0140-6736(22)00380-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00380-4</ArticleId><ArticleId IdType="pubmed">35427482</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner R, Jensen-Jarolim E, Pali-Schöll I. The ABC of clinical and experimental adjuvants—a brief overview. Immunol Lett. 2010;128:29–35. doi: 10.1016/j.imlet.2009.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2009.10.005</ArticleId><ArticleId IdType="pmc">PMC2999744</ArticleId><ArticleId IdType="pubmed">19895847</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki T, Nishijima M. Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum. Chem Pharm Bull (Tokyo) 1981;29:3611–3616. doi: 10.1248/cpb.29.3611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/cpb.29.3611</ArticleId><ArticleId IdType="pubmed">7340947</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang QH, Hu QX, Xie D, Chang BJ, Miao H, Wang Y, et al. Ganoderma lucidum exerts an anticancer effect on human osteosarcoma cells via suppressing the Wnt/β-Catenin signaling pathway. Integr Cancer Ther. 2019;18:1534735419890917. doi: 10.1177/1534735419890917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1534735419890917</ArticleId><ArticleId IdType="pmc">PMC6923688</ArticleId><ArticleId IdType="pubmed">31855073</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Liang YC, Lee SS, Chiang BL. Polysaccharide purified fromGanoderma luciduminduced activation and maturation of human monocyte-derived dendritic cells by the NF-κB and p38 mitogen-activated protein kinase pathways. J Leukoc Biol. 2005;78:533–543. doi: 10.1189/jlb.0804481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0804481</ArticleId><ArticleId IdType="pubmed">15894585</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Lee SS, Hou SM, Chiang BL. Polysaccharide purified from Ganoderma lucidum induces gene expression changes in human dendritic cells and promotes T helper 1 immune response in BALB/c mice. Mol Pharmacol. 2006;70:637–644. doi: 10.1124/mol.106.022327.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.106.022327</ArticleId><ArticleId IdType="pubmed">16670374</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Shih C, Cheng PY, Chin CL, Liou AT, Lee PY, et al. A polysaccharide purified from Ganoderma lucidum acts as a potent mucosal adjuvant that promotes protective immunity against the lethal challenge with Enterovirus A71. Front Immunol. 2020;11:561758. doi: 10.3389/fimmu.2020.561758.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.561758</ArticleId><ArticleId IdType="pmc">PMC7550786</ArticleId><ArticleId IdType="pubmed">33117346</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li J, Jin P, Wang Y, Zhu F. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev Vaccines. 2016;15:803–813. doi: 10.1080/14760584.2016.1191357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2016.1191357</ArticleId><ArticleId IdType="pubmed">27206811</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TT, Chiu CH, Lin CY, Chiu NC, Chen PY, Le TT, et al. Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2022;399:1708–1717. doi: 10.1016/S0140-6736(22)00313-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00313-0</ArticleId><ArticleId IdType="pubmed">35427481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YF, Chou CT, Lei HY, Liu CC, Wang SM, Yan JJ, et al. A mouse-adapted Enterovirus 71 strain causes neurological disease in mice after oral infection. J Virol. 2004;78:7916–7924. doi: 10.1128/JVI.78.15.7916-7924.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.15.7916-7924.2004</ArticleId><ArticleId IdType="pmc">PMC446098</ArticleId><ArticleId IdType="pubmed">15254164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Cheng PY, Chin CL, Huang LM, Lin SY, Chiang BL. Fibroblast-stimulating lipopeptide-1 as a potential mucosal adjuvant enhances mucosal and systemic immune responses to enterovirus 71 vaccine. Vaccine. 2018;36:4331–4338. doi: 10.1016/j.vaccine.2018.05.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2018.05.090</ArticleId><ArticleId IdType="pubmed">29891349</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SY, Hsu ML, Hsu HC, Lee SS, Shiao MS, Ho CK. The anti-tumor effect of Ganoderma lucidum is mediated by cytokines released from activated macrophages and T lymphocytes. Int J Cancer. 1997;70:699–705. doi: 10.1002/(SICI)1097-0215(19970317)70:6&lt;699::AID-IJC12&gt;3.0.CO;2-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0215(19970317)70:6&lt;699::AID-IJC12&gt;3.0.CO;2-5</ArticleId><ArticleId IdType="pubmed">9096652</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Chow YH, Huang LM, Hsieh SM, Cheng PY, Hu KC, et al. A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge. Sci Rep. 2018;8:10713. doi: 10.1038/s41598-018-28281-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-28281-5</ArticleId><ArticleId IdType="pmc">PMC6048030</ArticleId><ArticleId IdType="pubmed">30013088</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma S, Yu R, Mai Y, Yu N, Gao T, Yang J. Enhanced influenza immunity by nasal mucosal administration of the TPGS-modified liposomal vaccine. AAPS PharmSciTech. 2022;23:272. doi: 10.1208/s12249-022-02425-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-022-02425-3</ArticleId><ArticleId IdType="pubmed">36180652</ArticleId></ArticleIdList></Reference><Reference><Citation>Topol EJ, Iwasaki A. Operation nasal vaccine—lightning speed to counter COVID-19. Sci Immunol. 2022;7:eadd9947. doi: 10.1126/sciimmunol.add9947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.add9947</ArticleId><ArticleId IdType="pubmed">35862488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HY, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res. 1997;16:187–201. doi: 10.1007/BF02786362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02786362</ArticleId><ArticleId IdType="pubmed">9212364</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuper CF, Koornstra PJ, Hameleers DM, Biewenga J, Spit BJ, Duijvestijn AM, et al. The role of nasopharyngeal lymphoid tissue. Immunol Today. 1992;13:219–224. doi: 10.1016/0167-5699(92)90158-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-5699(92)90158-4</ArticleId><ArticleId IdType="pubmed">1627250</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis. 1991;13:926–939. doi: 10.1093/clinids/13.5.926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/13.5.926</ArticleId><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine. 2006;24:1238–1241. doi: 10.1016/j.vaccine.2005.09.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.09.029</ArticleId><ArticleId IdType="pubmed">16213632</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis GK, Pazgier M, Evans DT, Ferrari G, Bournazos S, Parsons MS, et al. Beyond viral neutralization. AIDS Res Hum Retroviruses. 2017;33:760–764. doi: 10.1089/aid.2016.0299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/aid.2016.0299</ArticleId><ArticleId IdType="pmc">PMC5695748</ArticleId><ArticleId IdType="pubmed">28084796</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Yin Y, Zhou C, Hou L, Cui Q, Zhang X, et al. Polysaccharides derived from Chinese medicinal herbs: a promising choice of vaccine adjuvants. Carbohydr Polym. 2022;276:118739. doi: 10.1016/j.carbpol.2021.118739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2021.118739</ArticleId><ArticleId IdType="pubmed">34823775</ArticleId></ArticleIdList></Reference><Reference><Citation>Firdaus FZ, Skwarczynski M, Toth I. Developments in vaccine adjuvants. Methods Mol Biol. 2022;2412:145–178. doi: 10.1007/978-1-0716-1892-9_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-0716-1892-9_8</ArticleId><ArticleId IdType="pubmed">34918245</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu MJ, Lee SS, Lin WW. Polysaccharide purified from Ganoderma lucidum inhibits spontaneous and Fas-mediated apoptosis in human neutrophils through activation of the phosphatidylinositol 3 kinase/Akt signaling pathway. J Leukoc Biol. 2002;72:207–216. doi: 10.1189/jlb.72.1.207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.72.1.207</ArticleId><ArticleId IdType="pubmed">12101282</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Tang Q, Zhang J, Xia Y, Yang Y, Wu D, et al. Triple helix conformation of β-d-glucan from Ganoderma lucidum and effect of molecular weight on its immunostimulatory activity. Int J Biol Macromol. 2018;114:1064–1070. doi: 10.1016/j.ijbiomac.2018.03.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2018.03.054</ArticleId><ArticleId IdType="pubmed">29548917</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q, Li L, Chen H, Liu Q, Wang Z. GPP (Composition of Ganoderma lucidum poly-saccharides and polyporus umbellatus poly-saccharides) enhances innate immune function in mice. Nutrients. 2019;11:1480. doi: 10.3390/nu11071480.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11071480</ArticleId><ArticleId IdType="pmc">PMC6682870</ArticleId><ArticleId IdType="pubmed">31261807</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, Ding R, Jiang S, Ji L, Pan M, Liu L, et al. The adjuvanticity of Ganoderma lucidum polysaccharide for Newcastle disease vaccine. Int J Biol Macromol. 2014;65:431–435. doi: 10.1016/j.ijbiomac.2014.01.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2014.01.067</ArticleId><ArticleId IdType="pubmed">24530324</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z, Zhu T, He J, Zhang Y, Gu P, Qiu T, et al. Adjuvanticity of Ganoderma lucidum polysaccharide liposomes on porcine circovirus type-II in mice. Int J Biol Macromol. 2019;141:1158–1164. doi: 10.1016/j.ijbiomac.2019.09.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijbiomac.2019.09.079</ArticleId><ArticleId IdType="pubmed">31520706</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandtzaeg P, Johansen F-E. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev. 2005;206:32–63. doi: 10.1111/j.0105-2896.2005.00283.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0105-2896.2005.00283.x</ArticleId><ArticleId IdType="pubmed">16048541</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglani L, Khader SA. Th17 cytokines in mucosal immunity and inflammation. Curr Opin HIV AIDS. 2010;5:120–127. doi: 10.1097/COH.0b013e328335c2f6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COH.0b013e328335c2f6</ArticleId><ArticleId IdType="pmc">PMC2892849</ArticleId><ArticleId IdType="pubmed">20543588</ArticleId></ArticleIdList></Reference><Reference><Citation>McGeachy MJ, Cua DJ, Gaffen SL. The IL-17 family of cytokines in health and disease. Immunity. 2019;50:892–906. doi: 10.1016/j.immuni.2019.03.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.021</ArticleId><ArticleId IdType="pmc">PMC6474359</ArticleId><ArticleId IdType="pubmed">30995505</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YW, Chang KC, Kao CH, Chang SP, Tung YY, Chen SH. Lymphocyte and antibody responses reduce Enterovirus 71 lethality in mice by decreasing tissue viral loads. J Virol. 2009;83:6477–6483. doi: 10.1128/JVI.00434-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00434-09</ArticleId><ArticleId IdType="pmc">PMC2698549</ArticleId><ArticleId IdType="pubmed">19386699</ArticleId></ArticleIdList></Reference><Reference><Citation>Siena E, Schiavetti F, Borgogni E, Taccone M, Faenzi E, Brazzoli M, et al. Systems analysis of human responses to an aluminium hydroxide-adsorbed TLR7 agonist (AS37) adjuvanted vaccine reveals a dose-dependent and specific activation of the interferon-mediated antiviral response. Vaccine. 2023;41:724–734. doi: 10.1016/j.vaccine.2022.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.12.006</ArticleId><ArticleId IdType="pubmed">36564274</ArticleId></ArticleIdList></Reference><Reference><Citation>Temizoz B, Ishii KJ. Type I and II interferons toward ideal vaccine and immunotherapy. Expert Rev Vaccines. 2021;20:527–544. doi: 10.1080/14760584.2021.1927724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2021.1927724</ArticleId><ArticleId IdType="pubmed">33993812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>